Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial

Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Objective. In a comparative conventional MRI, dynamic contrast-enhanced (DCE)-MRI, CT and radiography study, the authors aimed to monitor whether inflammation is reduced or even eliminated and damage halted in PsA patients receiving anti-TNF therapy.Methods. A 48-week prospective open-label investigator-initiated trial of 41 biologic-naive patients treated with 40 mg adalimumab every other week. Hand CT, MRI (according to the PsA MRI scoring system method) and radiography (Sharp-van der Heijde method) were obtained at weeks 0, 6 (only MRI), 24 and 48. Clinical response was assessed by the PsA Response Criteria (PsARC).Results. In the 23 PsARC responders at week 48, significant decreases from baseline in MRI synovitis (mean -2.0, P
Original languageEnglish
JournalRheumatology (Oxford, England)
Volume53
Issue number4
Pages (from-to)746-756
Number of pages10
ISSN1462-0324
DOIs
Publication statusPublished - Apr 2014

ID: 42707651